Erin Jensen
About
Erin Jensen is a scholar working on Surgery, Oncology and Epidemiology.
According to data from OpenAlex, Erin Jensen has authored 53 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Surgery, 18 papers in Oncology and 16 papers in Epidemiology. Recurrent topics in Erin Jensen's work include Cancer Immunotherapy and Biomarkers (15 papers), Lipoproteins and Cardiovascular Health (9 papers) and Pneumonia and Respiratory Infections (8 papers). Erin Jensen is often cited by papers focused on Cancer Immunotherapy and Biomarkers (15 papers), Lipoproteins and Cardiovascular Health (9 papers) and Pneumonia and Respiratory Infections (8 papers). Erin Jensen collaborates with scholars based in United States, France and Spain. Erin Jensen's co-authors include Murray A. Abramson, Tyler S. Finn, Kamal M.F. Itani, Ali Tafreshi, M. Catherine Pietanza, Andrew Robinson, Samuel E. Wilson, Samir S. Awad, Rina Hui and Silvia Novello and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Journal of the American College of Cardiology.
In The Last Decade
Erin Jensen
51 papers receiving 2.1k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Erin Jensen United States | 20 | 1.4k | 861 | 404 | 271 | 245 | 53 | 2.1k | ||
| Naoki Ishizuka Japan | 23 | 829 0.6× | 716 0.8× | 567 1.4× | 192 0.7× | 215 0.9× | 115 | 2.0k | ||
| Reury-Perng Perng Taiwan | 26 | 1.1k 0.8× | 1.6k 1.8× | 328 0.8× | 96 0.4× | 252 1.0× | 78 | 2.3k | ||
| Yu Yang Soon Singapore | 22 | 795 0.6× | 882 1.0× | 417 1.0× | 116 0.4× | 157 0.6× | 86 | 2.0k | ||
| Ji Yun Lee South Korea | 24 | 708 0.5× | 662 0.8× | 281 0.7× | 90 0.3× | 321 1.3× | 105 | 1.9k | ||
| Junshik Hong South Korea | 25 | 685 0.5× | 498 0.6× | 182 0.5× | 150 0.6× | 132 0.5× | 179 | 2.0k | ||
| Jennie R. Crews United States | 14 | 1.7k 1.2× | 591 0.7× | 124 0.3× | 107 0.4× | 289 1.2× | 26 | 2.4k | ||
| Rob J. Ouwendijk Netherlands | 21 | 664 0.5× | 566 0.7× | 546 1.4× | 151 0.6× | 197 0.8× | 63 | 1.5k | ||
| Lisa Derosa France | 25 | 1.7k 1.2× | 1.0k 1.2× | 321 0.8× | 337 1.2× | 184 0.8× | 111 | 3.2k | ||
| Antonis Valachis Sweden | 29 | 782 0.6× | 292 0.3× | 160 0.4× | 60 0.2× | 236 1.0× | 75 | 2.0k | ||
| Erin B. Kennedy United States | 22 | 1.9k 1.4× | 1.3k 1.5× | 727 1.8× | 117 0.4× | 510 2.1× | 41 | 3.2k |
Countries citing papers authored by Erin Jensen
Since
Specialization
Citations
This map shows the geographic impact of Erin Jensen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erin Jensen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erin Jensen more than expected).
Fields of papers citing papers by Erin Jensen
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Erin Jensen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erin Jensen. The network helps show where Erin Jensen may publish in the future.
Co-authorship network of co-authors of Erin Jensen
This figure shows the co-authorship network connecting the top 25 collaborators of Erin Jensen. A scholar is included among the top collaborators of Erin Jensen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erin Jensen. Erin Jensen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Li, Zhiqiang, Yue Kang, Yingpeng Zhao, et al.. (2025). Pooled data from phase 3 clinical trials comparing the clinical activity of ceftolozane/tazobactam versus meropenem for the treatment of complicated intra-abdominal infections. Infectious Diseases. 58(1). 40–51.
2.
Gadgeel, Shirish M., Delvys Rodríguez‐Abreu, Balázs Halmos, et al.. (2024). Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up. Journal of Thoracic Oncology. 19(8). 1228–1241.
3.
Shitara, Kohei, Yung‐Jue Bang, Lucjan Wyrwicz, et al.. (2024). Neoadjuvant/adjuvant pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo for gastric/gastroesophageal junction (G/GEJ) adenocarcinoma: Major pathologic response (mPR) in KEYNOTE-585.. Journal of Clinical Oncology. 42(16_suppl). 4073–4073.
4.
Johnson, Matthew G., Julie Strizki, Erin Jensen, et al.. (2024). Respiratory virus coinfections during the COVID-19 pandemic: epidemiologic analysis and clinical outcomes from the Phase 2/3 molnupiravir trial (MOVe-OUT). Microbiology Spectrum. 12(3). e0356323–e0356323.
5.
Novello, Silvia, Dariusz M. Kowalski, Alexander Luft, et al.. (2023). Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study. Journal of Clinical Oncology. 41(11). 1999–2006.
6.
Martín‐Loeches, Ignacio, Andrew F. Shorr, Marin H. Kollef, et al.. (2023). Participant- and Disease-Related Factors as Independent Predictors of Treatment Outcomes in the RESTORE-IMI 2 Clinical Trial: A Multivariable Regression Analysis. Open Forum Infectious Diseases. 10(6). ofad225–ofad225.
7.
Hamid, Omid, Caroline Robert, Adil Daud, et al.. (2021). Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006. European Journal of Cancer. 157. 391–402.
8.
Rini, Brian I., Michael B. Atkins, Elizabeth R. Plimack, et al.. (2021). Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial. European Urology Oncology. 5(2). 225–234.
9.
Timsit, Jean‐François, Jennifer A. Huntington, Richard G. Wunderink, et al.. (2021). Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial. Critical Care. 25(1). 290–290.
10.
Tóth, Peter P., Harold Bays, W. Virgil Brown, et al.. (2019). Comparing remnant lipoprotein cholesterol measurement methods to evaluate efficacy of ezetimibe/statin vs statin therapy. Journal of clinical lipidology. 13(6). 997–1007.e8.
11.
Davidson, Michael H., Joanne E. Tomassini, Erin Jensen, et al.. (2015). Time-related trends in variability of cIMT changes in statin trials. Data in Brief. 6. 530–541.
12.
Tóth, Peter P., Alberico L. Catapano, Michel Farnier, et al.. (2015). EZETIMIBE DOES NOT INCREASE FASTING GLUCOSE LEVELS MORE THAN STATINS ALONE IN NON-DIABETIC, HYPERCHOLESTEROLEMIC PATIENTS. Journal of the American College of Cardiology. 65(10). A1633–A1633.
13.
Farnier, Michel, John R. Guyton, Erin Jensen, et al.. (2013). Effects of ezetimibe, simvastatin and ezetimibe/simvastatin on correlations between apolipoprotein B, LDL cholesterol and non-HDL cholesterol in patients with primary hypercholesterolemia. Atherosclerosis. 229(2). 415–422.
14.
Bays, Harold, Scott Conard, Lawrence A. Leiter, et al.. (2010). Are post-treatment low-density lipoprotein subclass pattern analyses potentially misleading?. Lipids in Health and Disease. 9(1). 136–136.
15.
Wilson, Samuel E., Robin S. Turpin, Ritesh Kumar, et al.. (2008). Comparative Costs of Ertapenem and Cefotetan as Prophylaxis for Elective Colorectal Surgery. Surgical Infections. 9(3). 349–356.
16.
Itani, Kamal M.F., Erin Jensen, Tyler S. Finn, Joanne E. Tomassini, & Murray A. Abramson. (2008). Effect of Body Mass Index and Ertapenem versus Cefotetan Prophylaxis on Surgical Site Infection in Elective Colorectal Surgery. Surgical Infections. 9(2). 131–137.
17.
Namias, Nicholas, Joseph S. Solomkin, Erin Jensen, Joanne E. Tomassini, & Murray A. Abramson. (2007). Randomized, Multicenter, Double-Blind Study of Efficacy, Safety, And Tolerability of Intravenous Ertapenem Versus Piperacillin/Tazobactam in Treatment of Complicated Intra-Abdominal Infections in Hospitalized Adults. Surgical Infections. 8(1). 15–28.
18.
Itani, Kamal M.F., Samuel E. Wilson, Samir S. Awad, et al.. (2006). Ertapenem versus Cefotetan Prophylaxis in Elective Colorectal Surgery. New England Journal of Medicine. 355(25). 2640–2651.
19.
Hesley, Teresa M., Keith S. Reisinger, Bradley J. Sullivan, et al.. (2004). Concomitant administration of a bivalent Haemophilus influenzae type b-hepatitis B vaccine, measles-mumps-rubella vaccine and varicella vaccine: safety, tolerability and immunogenicity. The Pediatric Infectious Disease Journal. 23(3). 240–245.
20.
Lieberman, Jay M., Susan Partridge, Karen M. Kaplan, et al.. (2002). Kinetics of maternal hepatitis a antibody decay in infants: implications for vaccine use. The Pediatric Infectious Disease Journal. 21(4). 347–348.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Naoki Ishizuka Breakdown of academic impact, for papers by Reury-Perng Perng Breakdown of academic impact, for papers by Yu Yang Soon Breakdown of academic impact, for papers by Ji Yun Lee Breakdown of academic impact, for papers by Junshik Hong Breakdown of academic impact, for papers by Jennie R. Crews Breakdown of academic impact, for papers by Rob J. Ouwendijk Breakdown of academic impact, for papers by Lisa Derosa Breakdown of academic impact, for papers by Antonis Valachis Breakdown of academic impact, for papers by Erin B. Kennedy